Skip to main content

Institut Stvolovykh Kletok Cheloveka PAO (ISKJ.MCX) Stock Price and Company Information, 2024

Institut Stvolovykh Kletok Cheloveka PAO

ISKJ.MCX

Exchange: MCX
Currency Russian Rouble
ISIN: RU000A0JNAB6
Primary Ticker: ISKJ.MCX
Fiscal Year End: December
Gic Sector: Energy
Gic Group: Energy
Gic Industry: Oil, Gas & Consumable Fuels
Gic Sub Industry: Coal & Consumable Fuels
Description: Public Joint-Stock Company "Human Stem Cells Institute' operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation. The company also offers Neovasculgen, a gene-therapy drug for treatment of peripheral arterial disease, including critical limb ischemia; and SPRS-therapy (service for personal regeneration of skin), a set of personalized diagnostics and treatment procedures for repairing skin damages. In addition, it operates GENETICO, a medical genetics center and molecular diagnostic lab that provides a range of genetic analysis and counseling services for the early detection, prediction, and prophylactic treatment of genetic disorders, including reproductive system diseases; and provides preimplantation genetic diagnosis and screening that includes testing of developing embryos for monogenic inherited diseases and chromosome abnormalities during an in vitro fertilization cycle. Further, the company offers non-invasive prenatal testing of fetal chromosome abnormalities; and develops Gemacell, a cell-based drug candidate for treatment of myocardial infarction. Additionally, it provides range of diagnostic services for identification of genetic predisposition to oncological diseases; and distributes cell processing equipment. The company was founded in 2003 and is based in Moscow, Russia. Public Joint-Stock Company "Human Stem Cells Institute' is a subsidiary of PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy.
Address: 18/1 Olimpiysky prospect, Moscow, Russia, 129110
Website: https://hsci.ru
Updated On: 2023-10-16

Highlights

Market Capitalization: 10485610000
Market Capitalization Mln: 10485.61
EBITDA: 186032992
PE Ratio: 196.03
Book Value: 3.25
Earnings Share: 0.53
Most Recent Quarter: 2022-06-30
Profit Margin: 0.01
Operating Margin TTM: 0.11
Return On Assets TTM: 0.04
Return On Equity TTM: 16.01
Revenue TTM: 1143923968
Revenue Per Share TTM: 13.45
Quarterly Revenue Growth YOY: -0.06
Gross Profit TTM: 719400000
Diluted Eps TTM: 0.26
Quarterly Earnings Growth YOY: 0.11

Valuation

Trailing PE: 229
Price Sales TTM: 3.90
Price Book MRQ: 25.90
Enterprise Value: 6192044000
Enterprise Value Revenue: 5.41
Enterprise Value Ebitda: 34.46

Technicals

Beta: 1.29
50 Day MA: 72.93
200 Day MA: 76.35

Splits & Dividends

Ex Dividend Date: 2016-06-29

Earnings

Report Date: 2017-12-31
Date: 2017-12-31
Currency: RUB
Eps Actual: -1.10
Report Date: 2017-10-31
Date: 2017-09-30
Before After Market: After Market
Currency: RUB
Eps Actual: 0.33
Report Date: 2017-08-01
Date: 2017-06-30
Before After Market: After Market
Currency: RUB
Eps Actual: -0.32
Report Date: 2017-05-02
Date: 2017-03-31
Before After Market: After Market
Currency: RUB
Eps Actual: -0.26
Report Date: 2017-03-30
Date: 2016-12-31
Before After Market: After Market
Currency: RUB
Eps Actual: -0.08
Report Date: 2016-09-30
Date: 2016-09-30
Currency: RUB
Eps Actual: -0.55
Report Date: 2016-06-30
Date: 2016-06-30
Currency: RUB
Eps Actual: -0.74
Report Date: 2016-03-31
Date: 2016-03-31
Currency: RUB
Eps Actual: -0.09
Date: 2017-12-31
Eps Actual: -1.36
Date: 2016-12-31
Eps Actual: -1.48